Ted started at Orthovita and reaped on-job-training benefits of a fast growing start-up with their flagship medical device Vitoss bone graft substitute (bgs).
Ted led the product development collaboration with Kensey Nash Corporation (now DSM Biomedical) who partnered with Orthovita to develop and commercialize
Vitoss Foam bgs with additional handling benefits with bovine collagen.
Stryker acquired Orthovita and Ted led the Stryker Orthobiologics Research & Product development team until switching career gears and moved to DSM Biomedical for a Commercial role. At DSM, Ted managed the largest commercial territory and grew his sales by 10% CAGR for past 5 years. Recently, Ted moved into S&BD role and is responsible for extending the DSM Biomedical Innovation team with external partners and forming alliances. Additionally, Ted conducts diligence on DSM Biomedical acquisition targets.
Ted led the product development collaboration with Kensey Nash Corporation (now DSM Biomedical) who partnered with Orthovita to develop and commercialize
Vitoss Foam bgs with additional handling benefits with bovine collagen.
Stryker acquired Orthovita and Ted led the Stryker Orthobiologics Research & Product development team until switching career gears and moved to DSM Biomedical for a Commercial role. At DSM, Ted managed the largest commercial territory and grew his sales by 10% CAGR for past 5 years. Recently, Ted moved into S&BD role and is responsible for extending the DSM Biomedical Innovation team with external partners and forming alliances. Additionally, Ted conducts diligence on DSM Biomedical acquisition targets.